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 Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer 
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Our previous study has established that Glypican-3 (GPC3) is a promising target for 
immunotoxin therapy in hepatocellular carcinoma (HCC). GPC3 targeting immunotoxins can 
inhibit HCC cell proliferation by blocking Wnt binding and through the elimination of cellular 
protein synthesis. While immunotoxins have shown great success in the clinical for treating 
blood cancers, in particular hairy cell leukemia, the same clinical success has not been 
demonstrated in treating solid tumors. We believe that modification of the Pseudomonas toxin 
domain may help to overcome clinical limitations associated with the treatment of solid tumors. 
Clinical limitations include off-target toxicity associated with the development of vascular leak 
syndrome, a short serum half-life and the development of a neutralizing antibody responses. To 
understand the effect of deimmunization on the immunotoxins’ cytotoxic function, in the present 
study we constructed a panel of anti-GPC3 immunotoxins with point mutations to remove 
antigen residues predicted to be involved in B cell, T cell, or a combination of both responses. 
The deimmunizied immunotoxins exhibited similar levels of cytotoxic function in cell 
proliferation assays. All of the deimmunized versions showed a significant increase in overall 
survival as determined by Hep3B subcutaneous and HuH-7 intraperitoneal mouse models. The 
new deimmunized immunotoxins appear to be well tolerated in mice. To improve their serum 
half-life, we are further engineering the immunotoxins by incorporating albumin binding 
domains. The optimized immunotoxin will be clinically developed for the treatment of liver 
cancer.  
